NO20074090L - Orale vaksiner for fisk - Google Patents

Orale vaksiner for fisk

Info

Publication number
NO20074090L
NO20074090L NO20074090A NO20074090A NO20074090L NO 20074090 L NO20074090 L NO 20074090L NO 20074090 A NO20074090 A NO 20074090A NO 20074090 A NO20074090 A NO 20074090A NO 20074090 L NO20074090 L NO 20074090L
Authority
NO
Norway
Prior art keywords
fish
oral
complexes
relates
protein complex
Prior art date
Application number
NO20074090A
Other languages
English (en)
Inventor
Dionisius Elisabeth An Florack
Hendrik Jan Bosch
Original Assignee
Wageningen Business Generator
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wageningen Business Generator filed Critical Wageningen Business Generator
Publication of NO20074090L publication Critical patent/NO20074090L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Fodder In General (AREA)
  • Feed For Specific Animals (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Oppfinnelsen angår utvikling, blanding og fremstilling av mukosale (orale) vaksiner for fisk. Nærmere bestemt angår oppfinnelsen proteinkomplekser for levering av antigener til og gjennom mukosale overflater hos fisk for induksjon av en immunrespons, og fremstilling av nevnte komplekser i en vertscelle, foretrukket planter. Det tilveiebringes anvendelse av et proteinkompleks omfattende et antigen av interesse fusjonert til B-subenheten av Vibrio cholerae koleratoksin (CT-B), eller Escherichia coli varmelabilt enterotoksin (LT-B) for fremstilling av en oral fiskevaksine. Likeså tilveiebringes fiskefôr omfattende et proteinkompleks ifølge oppfinnelsen.
NO20074090A 2005-01-26 2007-08-08 Orale vaksiner for fisk NO20074090L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05075203A EP1685848A1 (en) 2005-01-26 2005-01-26 Oral vaccines for fish
PCT/NL2006/000044 WO2006080842A2 (en) 2005-01-26 2006-01-26 Oral vaccines for fish

Publications (1)

Publication Number Publication Date
NO20074090L true NO20074090L (no) 2007-10-24

Family

ID=34938018

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074090A NO20074090L (no) 2005-01-26 2007-08-08 Orale vaksiner for fisk

Country Status (8)

Country Link
US (1) US20080274126A1 (no)
EP (2) EP1685848A1 (no)
JP (1) JP2008531478A (no)
AU (1) AU2006209101A1 (no)
CA (1) CA2595913A1 (no)
CR (1) CR9269A (no)
NO (1) NO20074090L (no)
WO (1) WO2006080842A2 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120088819A1 (en) * 2008-10-31 2012-04-12 Makoto Inoue Method for enhancing expression of recombinant protein
EP2412721A4 (en) 2009-03-26 2012-08-29 Univ Tokyo Nat Univ Corp KOI HERPESVIRUS SPECIFIC ANTIBODY AND ANTIGEN THEREOF
CL2009001197A1 (es) * 2009-05-15 2009-08-21 Farm En Aquacultura Veterinaria Fav S A Composicion farmaceutica veterinaria que contiene la variedad chilena del virus de la anemia infecciosa del salmon, marcadores proteicos y excipientes farmaceuticasmente aceptables; procedimiento de obtencion del virus; uso de la composicion para preparar una vacuna destinada a la prevencion del virus isa.
US8999319B2 (en) * 2010-06-09 2015-04-07 Mississippi State University Oral vaccination of fish with live attenuated Edwardsiella ictaluri vaccines
EP2753686A4 (en) 2011-09-09 2015-06-03 Advanced Bionutrition Corp BIVALENT IPNV ISAV VACCINE USING A VIRUS LIKE PARTICLE PLATFORM AND USE METHOD THEREFOR
CN107056898A (zh) * 2017-02-13 2017-08-18 中国水产科学研究院珠江水产研究所 鲤疱疹病毒3型1301株orf136基因重组表达蛋白、抗体及其应用
CN110747219A (zh) * 2019-11-29 2020-02-04 浙江省淡水水产研究所 一种可添加于饲料中的鲤鱼鲤春病毒血症口服疫苗
BR112022017032A2 (pt) * 2020-02-25 2022-10-11 Migal Galilee Res Institute Ltd Composições compreendendo ltb e antígenos patogênicos, e uso das mesmas.
CN113951183B (zh) * 2021-11-19 2022-10-25 莱州明波水产有限公司 黄带拟鲹亲鱼培育方法
CN118574934A (zh) * 2022-02-11 2024-08-30 因特尔乌斯生物治疗公司 促融合弹状病毒糖蛋白及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354555A (en) * 1985-04-10 1994-10-11 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Vaccine to control the viral infection of fish
GB9112553D0 (en) * 1991-06-11 1991-07-31 Wellcome Found Fusion proteins
DE69533964T2 (de) * 1994-10-24 2006-03-30 The Texas A & M University System, College Station Orale immunisierung durch verwendung von transgenen pflanzen
US20030165543A1 (en) * 2000-01-27 2003-09-04 Langridge William H.R. Transgenic plant-based vaccines
WO1999018225A1 (en) * 1997-10-07 1999-04-15 Loma Linda University Expression of cholera toxin b subunit in transgenic plants and efficacy thereof in oral vaccines
EP1522585A1 (en) * 2003-10-09 2005-04-13 Plant Research International B.V. Chimeric carrier molecules for the production of mucosal vaccines

Also Published As

Publication number Publication date
WO2006080842A3 (en) 2006-09-14
JP2008531478A (ja) 2008-08-14
CA2595913A1 (en) 2006-08-03
US20080274126A1 (en) 2008-11-06
EP1685848A1 (en) 2006-08-02
WO2006080842A2 (en) 2006-08-03
AU2006209101A1 (en) 2006-08-03
CR9269A (es) 2007-11-23
EP1850868A2 (en) 2007-11-07

Similar Documents

Publication Publication Date Title
Song et al. Vaccine strategies to elicit mucosal immunity
Shahid et al. Plant‐based oral vaccines against zoonotic and non‐zoonotic diseases
Hansson et al. Design and production of recombinant subunit vaccines
Nian et al. Development of nasal vaccines and the associated challenges
Saggese et al. The bacterial spore as a mucosal vaccine delivery system
HRP20240847T1 (hr) Novi polisaharid i njegove upotrebe
Yu et al. Immunogenicity of eGFP-marked recombinant Lactobacillus casei against transmissible gastroenteritis virus and porcine epidemic diarrhea virus
Taechavasonyoo et al. The immune-adjuvant effect of Japanese flounder Paralichthys olivaceus IL-1β
JP2015535259A5 (no)
CR9269A (es) Vacunas orales para peces
Otczyk et al. Mucosal immunization: a realistic alternative
RU2011140858A (ru) Конъюгаты гаптен-носитель, содержащие в качестве носителя бактериальные токсины, обладающие сигнальным пептидом, и их применение в иммуногенных композициях
Isticato Bacterial spore-based delivery system: 20 years of a versatile approach for innovative vaccines
WO2007098718A8 (es) Antígenos vacunales quiméricos contra el virus de la influenza aviar
Salvador-Erro et al. Targeting Enterotoxins: Advancing vaccine development for enterotoxigenic Escherichia coli ETEC
Bhatia et al. Edible vaccines
Juárez-Montiel et al. The corn smut (‘Huitlacoche’) as a new platform for oral vaccines
Debnath et al. Insight of oral vaccines as an alternative approach to health and disease management: An innovative intuition and challenges
Uddin et al. Mucosal immunization with spore-based vaccines against Mannheimia haemolytica enhances antigen-specific immunity
Sung et al. RETRACTED: Expression of SARS-CoV-2 Spike Protein Receptor Binding Domain on Recombinant B. subtilis on Spore Surface: A Potential COVID-19 Oral Vaccine Candidate
Pen et al. The outer membrane proteins and their synergy triggered the protective effects against pathogenic Escherichia coli
Wang et al. Porphyromonas gingivalis vaccine: antigens and mucosal adjuvants
Márquez-Escobar et al. Plant-based vaccines against respiratory diseases: Current status and future prospects
Uddin et al. Development of a spore-based mucosal vaccine against the bovine respiratory pathogen Mannheimia haemolytica
Maj et al. Oral administration of coronavirus spike protein provides protection to newborn pigs when challenged with PEDV

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application